| Vital Metals Limited (VML) ORDINARY FULLY PAID |
Materials |
$18 |
Vital Expands Tardiff Scoping Study to Include Niobium
|
28 Feb 2025 9:47AM |
$0.002 |
$0.003 |
risen by
100%
|
|
VML - Price-sensitive ASX Announcement
Full Release
Key Points
- Vital expands Tardiff Scoping Study to include niobium recovery.
- Niobium hosted in the same geological formations as rare earth minerals.
- Tardiff estimated to contain 636,000 tonnes of NdPr and 578,000 tonnes of Nb2O5.
- Initial metallurgical testwork showed a 15% recovery rate for niobium.
- Additional testwork will take approximately 8 weeks.
- Vital is working with the Canadian Government to establish a rare earths processing hub.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Clinical Labs Limited (ACL) ORDINARY FULLY PAID |
Health Care |
$589 |
Response to ASX Aware Letter
|
28 Feb 2025 9:46AM |
$3.270 |
$2.980 |
fallen by
8.87%
|
|
ACL - Price-sensitive ASX Announcement
Full Release
Key Points
- ACL issued guidance for FY25 revenue of $725M - $752M and underlying EBIT of $65M - $73M.
- ACL reaffirmed its guidance on multiple occasions including on 26 February 2025.
- All sell-side analysts' forecasts were within ACL's guidance range.
- ACL believes the release of its half-year reports will not materially affect its securities' price.
- ACL confirmed compliance with Listing Rules and has authorized the response to ASX.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Joyce Corporation Limited (JYC) ORDINARY FULLY PAID |
Consumer Discretionary |
$133 |
Dividend/Distribution - JYC
|
28 Feb 2025 9:46AM |
$4.580 |
$4.510 |
fallen by
1.53%
|
|
| Life360 Inc (360) CDI 3:1 FOREIGN EXEMPT XNGS |
Information Technology |
$5,591 |
SEC Form 10-K
|
28 Feb 2025 9:46AM |
$21.740 |
$32.130 |
risen by
47.79%
|
|
| Gorilla Gold Mines Ltd (GG8) ORDINARY FULLY PAID |
Materials |
$320 |
Lakeview High-Grade Intercepts Grow Mineralisation
|
28 Feb 2025 9:45AM |
$0.255 |
$0.510 |
risen by
100%
|
|
GG8 - Price-sensitive ASX Announcement
Full Release
Key Points
- Lakeview Prospect's mineralization extended to 400m strike length.
- Best gold intercepts include 19m @ 18.1 g/t Au and 11m @ 24.8 g/t Au.
- Lakeview is located 97km north of Kalgoorlie WA.
- Ongoing drilling at Lakeview and Mulwarrie.
- Lakeview gold mineralization associated with major fault and ultramafic rocks.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ReNerve Limited (RNV) ORDINARY FULLY PAID |
Health Care |
$11 |
1HFY25 Results Announcement
|
28 Feb 2025 9:45AM |
$0.135 |
$0.105 |
fallen by
22.22%
|
|
RNV - Price-sensitive ASX Announcement
Full Release
Key Points
- Strong Sales Growth: US sales increased by approximately 100% in 2024 compared to 2023.
- Revenue for 1H FY25 reached A$102,000, a 167% increase from the prior corresponding period.
- Global Expansion: New distribution agreements secured with Accession Medical Supplies and Union MediScience B.S.C.
- Clinical Advancements: The NervAlign® Nerve Guide Matrix showed positive animal study results.
- Successful IPO: Raised $7 million and listed on the ASX on 26 November 2024.
- Surgeon Feedback: Positive reception highlights the NervAlign® Nerve Cuff’s benefits.
- Strong Cash Position: Maintained a cash balance of $6.4 million as of 31 December 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Hydrix Limited (HYD) ORDINARY FULLY PAID |
Information Technology |
$4 |
Appendix 4D and Half Yearly Report
|
28 Feb 2025 9:45AM |
$0.020 |
$0.014 |
fallen by
30%
|
|
HYD - Price-sensitive ASX Announcement
Full Release
Key Points
- Hydrix Limited generated revenues of $5,597,012 for the half-year ending December 31, 2024.
- The company reported a loss of $635,660, showing improvement from the previous year's larger loss.
- Operating costs decreased significantly due to cost reduction initiatives.
- Hydrix Services reported its strongest calendar year of sales in the last 5 years.
- The company has a cash position of $1,117,925 as of December 31, 2024.
- 61% of revenue came from international clients.
- The company is focused on driving cash operating profit through sales conversions and higher margins.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ReNerve Limited (RNV) ORDINARY FULLY PAID |
Health Care |
$11 |
1HFY25 Appendix 4D and Half Year Report
|
28 Feb 2025 9:44AM |
$0.135 |
$0.105 |
fallen by
22.22%
|
|
RNV - Price-sensitive ASX Announcement
Full Release
Key Points
- ReNerve Limited reported a comprehensive loss of $1,843,656 for the half-year ending 31 December 2024.
- The loss increased by 29.8% compared to the previous year.
- The company raised $7 million through an IPO, and shares were listed on the ASX on 26 November 2024.
- US sales increased by around 100% compared to the previous year.
- Partnerships were formed with Accession Medical Supplies in Hong Kong and Mediscience B.S.C. in Bahrain to expand market reach.
- ReNerve is developing the NervAlign® Nerve Conduit and NervAlign® Nerve Guide Matrix with positive clinical outcomes.
- No dividends were declared during the reporting period.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Botanix Pharmaceuticals Ltd (BOT) ORDINARY FULLY PAID |
Health Care |
$716 |
Notification of cessation of securities - BOT
|
28 Feb 2025 9:44AM |
$0.455 |
$0.365 |
fallen by
19.78%
|
|
| Blackwall Limited (BWF) ORDINARY FULLY PAID |
Financials |
$62 |
Additional Dividend/Distribution - BWF
|
28 Feb 2025 9:44AM |
$0.410 |
$0.370 |
fallen by
9.76%
|
|
BWF - Price-sensitive ASX Announcement
Full Release
Key Points
- New announcement by Blackwall Limited regarding dividend distribution
- Total dividend distribution amount per security is AUD 0.025
- The dividend is fully franked
- Payment date is set for 08/04/2025
- Record date is 11/03/2025
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Carindale Property Trust (CDP) ORDINARY UNITS FULLY PAID |
Real Estate |
$393 |
Application for quotation of securities - CDP
|
28 Feb 2025 9:44AM |
$4.710 |
$4.750 |
risen by
0.85%
|
|
| Freelancer Limited (FLN) ORDINARY FULLY PAID |
Industrials |
$88 |
Appendix 3Y
|
28 Feb 2025 9:43AM |
$0.165 |
$0.195 |
risen by
18.18%
|
|
| Ora Banda Mining Ltd (OBM) ORDINARY FULLY PAID |
Materials |
$1,978 |
Sand King Update
|
28 Feb 2025 9:43AM |
$0.925 |
$1.050 |
risen by
13.51%
|
|
OBM - Price-sensitive ASX Announcement
Full Release
Key Points
- First Sand King Underground development ore processed through the Davyhurst plant with a reconciled grade 4.3% above expectations.
- Metallurgical recovery reconciled at 88.2%, which is 1.2% above the expected 87%.
- Early grade control drilling indicates a 19% uplift in gold ounce endowment thus far.
- Identification of at least three 'blow-out' zones in grade control drilling supports potential for bulk stoping opportunities.
- Capital projects now completed with commissioning of primary fan and escapeway in February.
- Sand King Underground remains on track to reach its steady state production rate in June.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Botanix Pharmaceuticals Ltd (BOT) ORDINARY FULLY PAID |
Health Care |
$716 |
Application for quotation of securities - BOT
|
28 Feb 2025 9:43AM |
$0.455 |
$0.365 |
fallen by
19.78%
|
|
| Kina Securities Limited (KSL) ORDINARY FULLY PAID |
Financials |
$329 |
FY24 Appendix 4E Preliminary Final Report
|
28 Feb 2025 9:42AM |
$1.170 |
$1.140 |
fallen by
2.56%
|
|
KSL - Price-sensitive ASX Announcement
Full Release
Key Points
- Net Profit After Tax of PGK 102.5 million for FY24.
- Underlying NPAT increased by 7% to PGK 111.9 million.
- Total revenue increased by 21% to PGK 488.8 million.
- Foreign exchange income surged 68% to PGK 86.2 million.
- Declared an unfranked final dividend of AUD 6.0 cents per share.
- Operating expenses rose by 31% to PGK 286.6 million.
- Capital adequacy ratio stands at 18.4%, above the required minimum.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Aumake Limited (AUK) ORDINARY FULLY PAID |
Consumer Discretionary |
$9 |
Aumake Appoints Dr. Anthony Noble as Non-Executive Chairman
|
28 Feb 2025 9:42AM |
$0.004 |
$0.003 |
fallen by
25%
|
|
| WEB Travel Group Limited (WEB) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,716 |
Notification of cessation of securities - WEB
|
28 Feb 2025 9:42AM |
$4.920 |
$4.750 |
fallen by
3.46%
|
|
| Blackwall Limited (BWF) ORDINARY FULLY PAID |
Financials |
$62 |
Dividend/Distribution - BWF
|
28 Feb 2025 9:42AM |
$0.410 |
$0.370 |
fallen by
9.76%
|
|
| Rox Resources Limited (RXL) ORDINARY FULLY PAID |
Materials |
$220 |
Notification regarding unquoted securities - RXL
|
28 Feb 2025 9:42AM |
$0.240 |
$0.300 |
risen by
25%
|
|
| Atomo Diagnostics Limited (AT1) ORDINARY FULLY PAID |
Health Care |
$12 |
Appendix 4D and Half Year Report ended 31 Dec 2024
|
28 Feb 2025 9:42AM |
$0.020 |
$0.018 |
fallen by
10%
|
|
AT1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 7% to AUD 2.05 million.
- Loss after tax reduced to AUD 2.76 million.
- Successfully secured a CRC-P grant for Active Syphilis test development.
- Focus on expanding point-of-care testing, especially for HIV.
- Cash at bank was AUD 2.9 million with no debt.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Dexus (DXS) FULLY PAID UNITS STAPLED SECURITIES |
Real Estate |
$7,518 |
December 2024 distribution payment
|
28 Feb 2025 9:41AM |
$7.450 |
$6.990 |
fallen by
6.17%
|
|
| Scentre Group (SCG) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$19,116 |
Application for quotation of securities - SCG
|
28 Feb 2025 9:41AM |
$3.450 |
$3.670 |
risen by
6.38%
|
|
| Amaero Ltd (3DA) ORDINARY FULLY PAID |
Industrials |
$186 |
Notice of Extraordinary General Meeting/Proxy Form
|
28 Feb 2025 9:41AM |
$0.285 |
$0.270 |
fallen by
5.26%
|
|
| Life360 Inc (360) CDI 3:1 FOREIGN EXEMPT XNGS |
Information Technology |
$5,591 |
Q4'24 Investor Presentation
|
28 Feb 2025 9:40AM |
$21.740 |
$32.130 |
risen by
47.79%
|
|
360 - Price-sensitive ASX Announcement
Full Release
Key Points
- $371.5 million in revenue for FY'24, up 22% YoY.
- 79.6 million global monthly active users.
- 2.3 million global paying circles.
- Strong subscription revenue growth of 26% including hardware subscriptions.
- Advertising revenue increased by 41%.
- Operating cash flow of $12.3 million in Q4'24.
- Projecting FY'25 revenue between $450 to $480 million.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Resonance Health Limited (RHT) ORDINARY FULLY PAID |
Health Care |
$18 |
Half Year Results Presentation
|
28 Feb 2025 9:40AM |
$0.060 |
$0.040 |
fallen by
33.33%
|
|
RHT - Price-sensitive ASX Announcement
Full Release
Key Points
- Group revenue reached $5.2 million, up 60% from the prior period.
- Normalised operating EBITDA rose to $0.54 million, a 35% increase.
- Free cash flow improved to $0.9 million, up 353% year-on-year.
- The company is structured into three segments: Central Imaging, CRO, and Investigator Sites.
- A major clinical trial contract worth $13.8 million was won.
- Positive cash receipts from customers totaled $8.3 million.
- The CRO business achieved total contract wins of $20.1 million since August 2023.
- The TrialsWest network continues to expand with new investigator sites planned.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
